BBB permeability HUREL, now part of Visikol, has experience in developing blood-brain barrier (BBB) assays and BBB model expansion, indicating potential for selling or cross-selling BBB-related tissue models, assays, and imaging services to pharmaceutical and biotech clients seeking CNS drug delivery solutions.

GLP imaging Visikol recently launched multiplex imaging services in a GLP setting, signaling a strong capability in validated, compliant imaging workflows that can underpin contract research engagements for drug discovery programs requiring robust tissue analysis and quantification.

Tissue slice models The suite of precision-cut tissue slice models for animal and human kidney and liver tissues presents a scalable platform for preclinical studies, enabling prospective clients to evaluate drug efficacy and toxicity in relevant ex vivo systems.

Imaging partnerships Strategic partnerships with Standard BioTools have historically boosted Visikol’s imaging capabilities, suggesting sales opportunities through co-marketing, bundled services, or joint projects with imaging platform providers to reach broader R&D audiences.

Growth potential With a 1M-10M revenue band and ongoing BBB and imaging service expansions, there is clear opportunity to cross-sell additional services to existing biotech clients seeking integrated imaging, tissue modeling, and permeability assessment capabilities.